discolpati-entdoc-thales-threes: Thanks (especially to discolpati). disco's info provides a pretty good basis for me to put this drug out of my mind as competition in the near term and affecting the government's Bavi broad spectrum anti-viral contracts. I was worried there might be another "promising" candidate out there to share the "broad spectrum" anti-viral money allotments with. I was concerned they could be in a position to get in on the broad spectrum anti-viral government monies and animal rule approval process if they were anywhere near starting phase 1 safety studies.
The following statement from disco's info says what type of progress they are making:
"it took us 4 years just to get to this point from our initial discovery of the compound--it is difficult to convince scientists when you propose a paradigm shift of how an antiviral should work. "
I like the line about how difficult it is to convince scientists when a paradigm shift in knowledge is involved. Seems to go hand in hand with the Bavi experience and waiting for the Nature article. Must be Barton (et. al) are having a hard time convincing their peers about the science too.
I don't mind as much about convincing peer review scientists when the price is moving nicely upwards.
Sounds like you may want to forward email to Thorpe and King. I believe we did license a mab from UCLA from a Dr. Chen. maybe we should tie this one up too. Maybe they would be synergistic.
On the other hand, since they haven't filed a patent yet maybe they will find out that there already is one filed for this work by Thorpe or Haynes.
News 
Market Data 
Discover 
